Unasnemab

尤那奈单抗

Report date: 2026/03/19 20:00:18

Base Information

Drug NameUnasnemab
Drug Alias NameAnti-protein repulsive guidance molecule-a antibodyAnti-RGMa antibodyAnti-RGMa humanized mAbMT-3921
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody humanized
Mechanisms of ActionAnti-Repulsive guidance molecule A
TargetsRepulsive guidance molecule A
Therapy Area/IndicationsSpinal Cord InjuriesSpinal Cord Diseases
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryCanadaUnited StatesJapan
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaN/A
Originator CompaniesOsaka UniversityMitsubishi Tanabe Pharma
China Registration ClassN/A

Develop Information

Active CompaniesMitsubishi Tanabe Pharma America IncMitsubishi Tanabe Pharma Corp
Inactive CompaniesN/A
Active IndicationsSpinal Cord InjuriesSpinal Cord Diseases
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A